A WHO report finds that progress on global health challenges has slowed, stalled, or even reversed.
An estimated 1.1 million people died from hepatitis B and 240,000 from hepatitis C in 2024.
Misalignment between new CDC recommendations and healthcare organizations creates vaccine implementation challenges for providers, a commentator says.
Of those exposed in utero or at birth, only 42% were tested, but that rate dropped to 32% by the end of the study period.
Prescribing is substantially below the estimated 260,000 annual treatment courses needed to achieve US elimination targets.
The University of Southern Denmark has placed a “full hold” on a heavily criticized clinical trial of the hepatitis B vaccine in Guinea-Bissau owing to ethical concerns.
Means defended removing the newborn dose of the hepatitis B vaccine from the childhood immunization schedule.
The country's foreign minister told Reuters the controversial trial is "not going to happen."
Rates climbed from 68% in January 2017 to a peak of 84% in February 2023 before dropping to 73% by August 2025.
Up to 90% of infants infected with hepatitis B at birth develop chronic liver infections.
